How Overhead Rates Affect Negotiations in the UK
Applied Clinical Trials
Institutional overhead remains one of the more contentious areas in clinical grant management. There can be substantial variations in these overhead rates from institution to institution with often times little immediately evident reason for the differences. Institution overhead rates in the United Kingdom seem to reflect that same imprecision.
Institutional overhead remains one of the more contentious areas in clinical grant management. There can be substantial variations in these overhead rates from institution to institution with often times little immediately evident reason for the differences. Institution overhead rates in the United Kingdom seem to reflect that same imprecision.
Unlike virtually any other developed country, the United Kingdom has a single health care provider, the National Health Service (NHS) in England and Wales, with comparable organizations in the other parts of the country. Yet overhead rates vary among the institutions conducting clinical research for commercial organizations.
Each year TTC reports on the relative costs of clinical grants around the world, drawing upon data in the GrantPlan database. Subscribers to this database conduct over 76% of all the commercial clinical trials. According to the data in GrantPlan, average institutional overhead rates in the United Kingdom have averaged around 25% percent over the last five years, an average figure substantially higher than the average institutional overhead rate, 17%, for the other countries in the European Union. Equally noteworthy is the range in institutional overheads across the NHS.
United Kingdom Institutional Overhead Quartiles
The median (and mean) overhead is 25%, with the lowest quartile at 20%. The highest quartile institutions haw overheads beginning at 30%. It appears that the institutions with the highest overheads though are the most willing to negotiate the actual overhead rate paid by the commercial organizations conducting research at that site. These highest quartile hospitals report an official overhead 10 points higher than actually accepted in the final clinical grant.—TTC (for more information, please contact help@ttc-llc.com).
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
